Attorney Jason T. Brown
If it's not right, we will fight.
Jersey City, NJ (PRWEB) June 30, 2014
The terms of the Nuvaring Master Settlement Agreement have been satisfied triggering a deadline of August to fund the $100 million dollar settlement fund, according to attorney Jason T. Brown. Last week the Federal Judge in St. Louis presiding over The Nuvaring Products Liability Litigation, Case Number: 4:08-md-01964-RWS, ordered the qualified settlement fund to be fully funded by August 13, 2014. The settlement was the culmination of seven years of litigation in which the plaintiffs alleged they suffered from blood clots from the use of Nuvaring. The venous thrombotic events alleged were pulmonary embolisms and deep vein thrombosis which often required the use of blood thinners for treatment. The defendants vigorously denied any liability and a bellwether case was headed to trial. The settlement was the result of secret negotiations that stretched over the course of many months.
The litigation itself lasted over seven years. Jason T. Brown, now of The JTB Law Group, LLC commended the result, “There was quite a bit of hard word by many talented lawyers to achieve this result,” Jason T. Brown stated. Mr. Brown was the first attorney in the country to file a battery of cases against the Nuvaring. The case is comparable to the allegations made in the Yaz litigation which resulted in over a billion dollars in payouts for women who alleged injuries of pulmonary embolisms, deep vein thrombosis, sagittal venous thrombosis, strokes and death from the use of Yaz, Yasmin, Ocella, Gianvi and Beyaz. “The difference in the result, is in the difference in the hormone and the FDA took action in the Yasmin litigation. In the Nuvaring litigation it did not,” Brown stated.
Attorney Jason T. Brown has a storied legal career, where he formerly served as a Special Agent and Legal Advisor to the Federal Bureau of Investigation. His firm The JTB Law Group, LLC represents clients nationwide, generally in class actions, mass torts, or catastrophic injuries. The mass torts the firm is currently investigating are alleged sprue-like enteropathy from the use of Benicar and alleged uncontrollable bleeding from Xarelto as well as still accepting cases on behalf of women injured by Yaz, Yasmin, Ocella, Gianvi and Beyaz.
“Any mass tort involves complicated politics and litigation. When many people are injured by the same product or circumstances it is known as a mass tort and the choice of counsel is an important one. Past successes don’t guarantee future results,” Brown stated. “If you’ve been injured, you should always speak with a qualified lawyer as soon as possible to protect you and educate you about your rights. If you don’t file a case in a certain timeframe you may forfeit your right to ever sue.”
For the Nuvaring litigation, the fund does not cover any future alleged injuries, nor does it cover individuals who did not opt-in to the fund. Women with alleged DVTs and PEs from Yaz and Yasmin can still participate in the Yasmin litigation.